RCAMU
DGX icon

Rothschild & Co Asset Management US’s Quest Diagnostics DGX Stock Holding History

Rothschild & Co Asset Management US’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,512
Closed -$502K – 401
2017
Q2 		$502K Sell
4,512
-301
-6% -$31.8K 0.01% 513
2017
Q1 		$473K Sell
4,813
-1,222
-20% -$116K 0.01% 511
2016
Q4 		$555K Buy
6,035
+679
+13% +$58.5K 0.01% 499
2016
Q3 		$453K Buy
+5,356
New +$450K 0.01% 493

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rothschild & Co Asset Management US's DGX Position: Q3 2017 in Review

Rothschild & Co Asset Management US sold out of Quest Diagnostics (DGX) in Q3 2017, closing a stake of 4,512 shares — an estimated $502K sold.

Rothschild & Co Asset Management US first reported a position in DGX in Q3 2016 and held it in 4 quarters. The position peaked at $555K in Q4 2016. 616 funds tracked by Wall St. Rank hold DGX as of Q3 2017.

  • Rothschild & Co Asset Management US reported no remaining Quest Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 4,512 Quest Diagnostics shares in Q3 2017, an estimated $502K.
  • Rothschild & Co Asset Management US first reported a position in Quest Diagnostics in Q3 2016 and held it in 4 quarters.
  • Rothschild & Co Asset Management US's Quest Diagnostics position peaked at $555K in Q4 2016.
  • 616 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2017.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2017, filed 8 Nov 2017.